Clinical Accelerator is pleased to announce a collaboration with HEPTA Medical, a pioneering medtech company developing next-generation therapeutic solutions for early-stage cancer treatment.

HEPTA Medical is at the forefront of innovation in thermal ablation technology. The company has developed a 𝗺𝗶𝗰𝗿𝗼𝘄𝗮𝘃𝗲 𝗮𝗯𝗹𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 that integrates an 𝗶𝗻-𝘀𝗶𝘁𝘂 𝗽𝗮𝘁𝗲𝗻𝘁𝗲𝗱 𝘁𝗶𝘀𝘀𝘂𝗲 𝘁𝗲𝗺𝗽𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝘀𝗲𝗻𝘀𝗼𝗿 with proprietary predictive software, enabling 𝗿𝗲𝗮𝗹-𝘁𝗶𝗺𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗮𝗻𝗱 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝗼𝗳 𝗮𝗯𝗹𝗮𝘁𝗶𝗼𝗻 𝗽𝗿𝗼𝗰𝗲𝗱𝘂𝗿𝗲𝘀 during treatment. This cutting-edge approach aims to improve precision and safety in the treatment of cancerous lesions, offering clinicians enhanced feedback throughout the procedure.

Under this collaboration, Clinical Accelerator will support HEPTA Medical in the execution and operational management of early-stage clinical trials that evaluate the safety and performance of their innovative platform. Leveraging our deep expertise in early-stage clinical research and global site networks, we will help accelerate the delivery of clinical evidence required for regulatory milestones and broader clinical adoption.

For more information on HEPTA Medical’s technology and mission, visit https://www.heptamed.com/.

We’re thrilled to announce that Clinical Accelerator is partnering with Angiolutions, a groundbreaking medtech company developing the A³-Shield®, the first-of-its-kind implant designed to stop the progression of abdominal aortic aneurysms (AAA) .

AAAs affect millions worldwide, with no available therapy to halt disease progression. Angiolutions’ innovation is based on pioneering research from Stanford University and represents the first major advance in the AAA field in over 30 years . By blocking harmful aortic pulse wave propagation, A³-Shield® has the potential to protect patients at the early stages of AAA, preventing growth and rupture — and saving lives. Through this collaboration, Clinical Accelerator will support Angiolutions in accelerating their early clinical development program, paving the way toward regulatory approvals and market access in both Europe and the U.S. We look forward to working together to bring this transformative therapy to patients who urgently need new solutions.

Clinical Accelerator, a leading CRO specializing in early-stage First-in-Human (FIH) and early feasibility MedTech studies, is pleased to announce its collaboration with Relief Cardiovascular on the FIH clinical trial of the Relief System. Full study approval has now been granted in Georgia, and preparations are underway to initiate the trial.

Innovating Fluid Management in Heart Failure

The trial will evaluate the Relief System, the world’s first transcatheter smart implant, which dynamically monitors and modulates cardiac preload and congestion. Unlike legacy passive monitoring systems, the Relief System implant autonomously captures multiparametric and hemodynamic data to guide device-driven pressure relief to optimize fluid balance and diuretic efficiency in patients with chronic heart failure. With its ability to monitor and control the implant via a remote cloud interface, the Relief System represents a new paradigm in heart failure: direct, tunable decongestion driven by a data-driven therapeutic implant.

A Strategic Location for Early-Stage Trials

Georgia’s robust clinical infrastructure combined with Clinical Accelerator’s regional experience enables rapid start-up, high-quality enrollment, and reliable data management. Clinical Accelerator will act as the CRO, overseeing regulatory liaison, site coordination, and trial operations, ensuring alignment with Relief Cardiovascular’s strategic objectives.

Next Steps

With study approval now in place, Clinical Accelerator and Relief Cardiovascular will move forward with site initiation and patient enrollment. The study is expected to generate valuable insights into the system’s clinical performance and therapeutic potential.

About Clinical Accelerator

Clinical Accelerator is an independent, academically connected, full-service CRO operating in Central and Eastern Europe and Central Asia. The company specializes in First-in-Human and early-phase studies for innovative MedTech and biotech companies, offering accelerated timelines, cost efficiency, and access to experienced clinical sites.
www.clinicalaccelerator.com

About Relief Cardiovascular

Relief Cardiovascular is a privately held company developing a novel transcatheter platform for improving fluid management in heart failure. Its transcatheter smart implant enables pressure-guided therapy, targeting patients who are resistant to conventional diuretic treatment.
www.reliefcardio.com

We’re proud to partner with Sutra Medical, a bold innovator in the structural heart space, as we support the early clinical development of their Sutra Hemi-Valve TMVR system — a unique approach that challenges conventional thinking in transcatheter mitral valve replacement.

While many TMVR systems aim to replace the entire mitral valve, Sutra takes a minimally disruptive route. Their device replaces only the posterior leaflet, allowing it to coapt naturally with the patient’s native anterior leaflet. The result?

• A design that preserves native valve anatomy,
• Has a small footprint in LV, and
• Eliminates risk of LVOT obstruction — a known complication with bulkier full-replacement systems.

This “hemi-valve” concept introduces a new category within mitral valve intervention — less invasive than full TMVR, yet potentially more durable than repair-based strategies. It’s especially promising for patients with complex anatomies or high surgical risk who might otherwise be left with limited options.

At Clinical Accelerator, we are proud to help bring such differentiated technologies into first-in-human studies and support companies that seek not just to improve, but to reimagine the way structural heart disease is treated.

We look forward to the journey ahead with Sutra Medical.

Learn more at sutramedical.com

Interventional heart failure management is emerging as a new and promising frontier in cardiovascular medicine, offering hope to patients with few effective treatment options. Among the innovators leading this transformation is Gradient Denervation Technologies, whose novel approach to pulmonary artery denervation has the potential to significantly improve outcomes for patients with pulmonary hypertension secondary to left heart disease.

Gradient Denervation Technologies, a Paris-based leader in cardiovascular innovation, has developed a minimally invasive, ultrasound-based system designed to target the nerves surrounding the pulmonary artery. By reducing sympathetic nervous system activity, this technology may help lower vascular resistance and pulmonary artery pressures—addressing a critical unmet need in this complex patient population.

We are pleased to see Gradient’s continued progress, following a strong and successful launch of their clinical program with the first-in-human (FIH) study conducted by Clinical Accelerator in Georgia. It has been an honor to support this initiative from its earliest stages, and we remain deeply committed to advancing pioneering therapies through trusted, strategic collaborations.

We also extend our sincere gratitude to Dr. Alex Rothman for his invaluable guidance and support to the Georgian clinical team throughout the execution of Gradient’s FIH study. We look forward to the continued advancement and success of this vital clinical program.